BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

Reuters

2025/04/03

April 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:

ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE
ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025
ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025
ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS

Source text: ID:nBw4Hk80Pa

Further company coverage: ALDX.O

(((( Reuters.briefs@thomsonreuters.com ;));))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524625614"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524625614\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524625614?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524625614","market":"nz","top_or_hot":-1,"title":"BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease</title></head><body><p><span>April 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a> <span>ALDX.O</span>:</p><ul><li><p>ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE</p></li><li><p>ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025</p></li><li><p>ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025</p></li><li><p>ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS</p></li></ul><p>Source text: <span>ID:nBw4Hk80Pa</span></p><p>Further company coverage: <span>ALDX.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-03 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease</title></head><body><p><span>April 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a> <span>ALDX.O</span>:</p><ul><li><p>ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE</p></li><li><p>ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025</p></li><li><p>ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025</p></li><li><p>ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS</p></li></ul><p>Source text: <span>ID:nBw4Hk80Pa</span></p><p>Further company coverage: <span>ALDX.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0K9:1","article_id":"2524625614","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524625614","pubTimestamp":1743682393,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye DiseaseApril 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALDX":"Aldeyra Therapeutics Inc"},"translate_title":"BRIEF-Aldeyra收到FDA关于Reproxalap治疗干眼症新药申请的完整回复函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9},"content_text":"BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye DiseaseApril 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASEALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTSSource text: ID:nBw4Hk80PaFurther company coverage: ALDX.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}